Irit Arbel
Independent Vice Chair of the BoardDr. Irit Arbel, DSc, Ph.D, serves as Independent Vice Chair of the Board at Brainstorm Cell Therapeutics Inc. since March 2020. Dr. Arbel had been an Executive Vice President of Research and Development at Online Disruptive Technologies, Inc. since July 30, 2012 until August 2018 and also serves as its Director. Dr. Arbel serves as a National Sales Manager of Laboratoires Merck Sharp & Dohme-Chibret SNC. Dr. Arbel served as an Independent Director of Isracann Biosciences Inc. (fka Atlas Blockchain Group Inc.) since October 07, 2019 until December 15, 2022. Dr. Arbel served as Chief Executive Officer of Neurochords Corp from August 2018 to 2020. Dr. Arbel is a Member of the RFB Investment House management team. Dr. Arbel has management experience in the areas of cell therapy, medical devices and pharmaceuticals. Dr. Arbel was the co-Founder and Chairperson of several medical device companies including Real Aesthetics Inc from 2009 to 2011 and BRH Medical. She is CEO and Director of Neurocords Corp. since September 2018. Dr. Arbel served as the President of Brainstorm Cell Therapeutics Inc. (Former Name: Golden Hand Resources Inc.) from April 28, 2004 to November 8, 2004 and served its Principal Executive Officer and Principal Accounting Officer until November 8, 2004. Dr. Arbel founded Brainstorm Cell Therapeutics Inc in May 2004 and served as its Chairperson since April 2014 until March 2020 and Director since joining in May 2004. Dr. Arbel served as the President and Chief Executive Officer of Pluristem Therapeutics, Inc. (formerly AI Software Inc.) from May 30, 2003 to June 10, 2004. Dr. Arbel served as Executive Vice President, Research and Development at Savicell Diagnostic Limited from July 2012 until July 2018 and served as its Co-Founder. She has conducted research in the fields of Alzheimer disease, immunology and osteoporosis with numerous publications, Dr. Arbel has a wealth of Managerial experience through her position as Israeli Sales Manager of Merck, Sharp & Dohme Ltd. (MSD) from February 1998 to December 2002. Dr. Arbel was President and Chief Executive Officer of Pluristem Life Systems since June 2002 until May 2004, a biotechnology company and prior to that, Israeli Sales Manager of Merck, Sharp & Dohme, a pharmaceutical company. From 1995 to 1997, Dr. Arbel served as the Head of research for Hadassa - Ein Karem Hospital in Jerusalem, Israel. Dr. Arbel specialized in the use of pharmaceuticals for neurology, ophthalmology and dermatology treatments. Dr. Arbel has been a Director of Pluristem Therapeutics, Inc. from May 30, 2003 to June 10, 2004. Dr. Arbel is a Member of the Neurological Association and American Society of Hematology. Dr. Arbel also holds a Chemical Engineering degree from the Technion, Israel Institute of Technology. Dr. Arbel received a Bachelor's Degree in Biology from Hebrew University in 1983 and a Masters and PHD in Medical Sciences from Technion University in 1988. Dr. Arbel earned her Post Doctorate degree in 1997 in Neurobiology from Hadassah Hospital Neurological Department. Dr. Arbel has a Doctor of Science (D.Sc.) in Neurology from The Technion Medical School.
Positions
- Company NameBrainstorm Cell Therapeutics Inc.Stock CodeBCLIPositionIndependent Vice Chair of the BoardColleagues
- CLChaim LebovitsPresident & CEO
- PJPeter J. PittsChief Strategic Regulatory and Policy Officer & Executive Chairman
- UYUri YablonkaExecutive VP, Chief Business Officer, Secretary & Director
- APAlla PatlisInterim CFO & Controller
- HHHartoun HartounianExecutive VP & COO
- JCJerold ChunChairman of Scientific Advisory Board
- NNNir NaorIndependent Director
